Biocon Biologics Ltd launches biosimilar HULIO in US
Bengaluru: Biocon Biologics Ltd announced that HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available to patients in the US after five years of experience in Europe and two years in Canada.
HULIO meets the rigorous biosimilar approval standards of the FDA. Like Humira, HULIO is citrate-free and is made without natural rubber latex (to help reduce hypersensitivity reactions). Biocon Biologics also offers HULIO360, a robust patient support programme, which includes benefits verification and prior authorisation support, copay assistance, a bridge programme for eligible patients, and at-home nurse injection training.
“The launch of HULIO, our biosimilar adalimumab, in the United States is an important milestone for Biocon Biologics as it expands our well-known biosimilar product offering to patients in the United States,” said Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd.
“Biocon Biologics is pleased to make HULIO, a patient-friendly, 2-click, prefilled pen available in the United States for patients with certain inflammatory diseases. There are no buttons to push. Patients remove the cap and push the device against their skin to trigger their injection. Designed and built with patients in mind, healthcare professionals and patients don’t have to miss a beat with HULIO; they simply, ‘Click, Click, Go,’” said Mathew Erick, Chief Commercial Officer, Advanced Markets, Biocon Biologics Ltd.
Source – ETHealth World
